Table 2.
Characteristics of included studies investigating body image (BI) in baseline and during treatment females with breast cancer (BC)
| Study | CO | Before treatment | During treatment | Age (mean/ range) | Tumor size/cancer stage | Treatment | BI QU | Qualityof study | ||
|---|---|---|---|---|---|---|---|---|---|---|
| N | BI score, mean (SD) | N | BI score, mean (SD) | |||||||
| Aerts et al., 2014 | BE | 81 |
1.53 (3.48) |
66 |
4.05 (5.52) |
57/ 34–75 |
na./ Early stage BC |
Surgery, Chemotherapy, Radiotherapy, Endocrine therapy |
EORTC QOL-BR23 | NOS: 6 |
| Bueno et al., 2018 | BR | 166 |
84.50 (23.40) |
166 |
80.60 (26.80) |
59/ na |
na./ na |
Surgery | EORTC QOL-BR23 | NOS: 4 |
| Browall et al., 2008 | SE | 75 |
90.00 (18.00) |
65 |
66.00 (30.00) |
64/ 55–80 |
na./ Stage I: 23 Other stages: 52 |
Chemotherapy, Radiotherapy, Endocrine therapy, Surgery |
EORTC QOL-BR23 | NOS: 6 |
| Rahman et al., 2015 | BD | 250 |
86.00 (7.83) |
250 |
70.46 (6.36) |
44/ 21–67 |
T1: 15 T2: 102 T3: 53 T4: 80/ na. |
Mastectomy, Neoadjuvant chemotherapy | EORTC QOL-BR23 | NOS: 8 |
| Viller et al., 2017 | SPA | 180 |
94.20 (13.20) |
180 |
85.10 (23.00) |
58/ na |
na./ 0 : 22 I : 149 II : 128 III : 35 IV: 2 |
Chemotherapy, Radiotherapy, Hormone therapy, Biological therapy anti-Her2 |
EORTC QOL-BR23 | NOS: 8 |
| Binotto et al., 2020 | BR | 33 |
90.66 (14.99) |
33 |
66.41 (31.49) |
51/ na. |
na./ Stage 1, 2 and 3 |
Surgery, Adjuvant or Neoadjuvant Taxane-based chemotherapy |
EORTC QOL-BR23 | NOS: 6 |
| Castro e Silva et al., 2022 | BR | 80 |
25.73 (18.57) |
80 |
34.06 (6.10) |
52/ X |
na./ Any at stage |
Surgery, Chemotherapy |
EORTC QOL-BR23 | NOS: 5 |
| Bahar et al., 2023 | TUR | 259 |
87.00 (18.00) |
197 |
94.00 (13) |
51/ 24–84 |
na./ I: 95 II: 156 III: 206 |
Radiotherapy, Surgery, Chemotherapy, Hormone therapy |
EORTC QOL-BR23 | NOS: 5 |
| El Haidari et al., 2023 | LB | 120 |
89.20 (17.70) |
116 |
81.00 (21.60) |
54/ na. |
T1: 42 T2: 71 missing: 7/ I: 52 II: 68 |
Surgery | EORTC QOL-BR23 | NOS: 5 |
| *Parker et al., 2007 | USA | 104 |
23.80 (5.50) |
104 |
22.60 (6.10) |
53/ na |
na./ stage I and II |
Chemotherapy, Radiotherapy, Surgery |
EORTC QOL-BR23 | NOS: 8 |
| *Gadisa et al., 2021 | ET | 146 | na | na | na |
42/ na |
I: 6 II: 48 III: 64 IV: 28 |
Chemotherapy | EORTC QOL-BR23 | NOS: 7 |
| *Laroche et al., 2017 | FR | 109 |
66.00 (33) |
109 | na |
61/ na. |
Early stage BC |
Surgery, Chemotherapy, Aromatase inhibitor |
EORTC QOL-BR23 | NOS: 4 |
| *Carver et al., 1998 | USA | 66 | na | 61 | na |
52/ 28–76 |
I: 49 II: 17 |
Surgery, Chemotherapy, Hormone therapy, Radiotherapy |
MBA | NOS: 3 |
| *Metcalfe et al., 2012 | CA | 24 | na | 24 | na |
53/ 30–83 |
0: 19 I: 26 II: 41 III: 14 |
Surgery, Radiotherapy |
BIBC | NOS: 5 |
SD standard deviation, BIS body image scale (Hopwood et al. 2001), BIS* body image scale- modified version (Polivy et al. 1977), EORT QoL-BR 23 european organization for research and treatment of cancer quality of life in patients with breast cancer (Sprangers et al. 1996), BIBC body image after breast cancer (Baxter, 1997), MBA measure of body apperception (Carver et al. 1998), NOS newcastle-ottawa scale, na. missing data, BI QU body image related questionnaires, * studies in only qualitative analysis, CO country, CA Canada, FR France, ET Ethiopia, LB Lebanon, TUR Turkey, BR Brazil, SPA Spain, BE Belgium, BD Bangladesh, SE Sweden